Edgy indeed, Andrew D. Huberman, Ph.D.! When we pioneered this space by starting $ATAI and $CMPS around 8 years ago, we were met with A LOT of skepticism from the traditional (neuropsychiatry) drug development community - we were literally laughed out of rooms. It took a lot of focused hard

Interesting new mechanistic insights on Ketamine. The authors of a new study just published yesterday in Nature Medicine investigated the potential role of the opioid system in modulating glutamatergic effects of ketamine, demonstrating that naltrexone pre‑treatment reduced

What If Psilocybin Could Reopen the Brain’s Ability to Heal? Our foundation is proud to support this groundbreaking study led by the incredible Gul Dolen at Johns Hopkins with a grant to add MRI imaging before and after psilocybin administration (details in comments below). This

🇩🇪🍄Germany rarely takes the lead in (regulatory) innovation these days - so it’s encouraging to see the country where we founded $ATAI emerging as a thought leader when it comes to compassionate access programs with psychedelics! In contrast to systems like that of Health